Humanigen
company
About
Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $80M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
6
$163M
Humanigen has raised a total of
$163M
in funding over 2 rounds. Their latest funding was raised on
Mar 10, 2021 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 10, 2021 | Post-IPO Debt | $80M | 1 |
Hercules Capital
|
— | Detail |
| Jul 1, 2016 | Post-IPO Equity | $11M | 1 | — | — | Detail |
| Dec 22, 2008 | Series D | $12M | 1 | — | — | Detail |
| Sep 23, 2008 | Series D | $20M | 2 | — | — | Detail |
| Aug 3, 2007 | Series C | $20M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
Humanigen is funded by 4 investors.
Hercules Capital
and Nomis Bay
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Post-IPO Equity |
|
|
— | Series D |
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
